Top news of the week: 01.04.2021.
Healthcare
Former Merck Exec Joins Flagship to Helm AI Startup Generate Biomedicines
Michael T. Nally became the latest Merck executive to join Flagship Pioneering, taking the reins of its machine learning protein therapy company Generate Biomedicines.
Digital Health: From Pharma To…Fitness?
Astute TR readers might have noticed that I’ve been writing a lot about digital fitness lately, in contrast to digital pharma. This is deliberate, and represents an evolution of my ...
NICE methods and process review aims to create fertile ground for innovation
The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK?
Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates
One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease.
Asian Americans in Biotech: Breaking the Silence
As a first generation Asian-American working in biotech in San Diego, I identified with the many good points in Kevin Kwok’s piece on Mar. 9 about the rise in hate crimes. Fast forward to ...
What is the biggest benefit technology will have on ageing and longevity?
Members of the Global Future Council on Healthy Ageing and Longevity share ideas on how technology will enable people to live healthier, more fulfilling lives at all ages.
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838
Immunic, Inc. (Nasdaq: IMUX) today announced management’s participation in the following industry and investor conferences in March:
A Glimpse Into a Price-Controlled Future
Imagine if H.R. 3 — the drug price-control bill that has significant support in the House of Representatives — were to become law. What would it look like if some of the bill’s provisions, ...